News from Novartis Pharmaceuticals Corporation A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages

Latest

Dec 02, 2018, 10:24 ET Real-world data show Novartis drug Promacta® improves outcomes for ITP patients compared to other second-line therapies

Novartis announced results of a retrospective, real-world evidence study in patients with immune thrombocytopenia (ITP) treated with Promacta®...


Dec 01, 2018, 10:26 ET Novartis announces new crizanlizumab (SEG101) data analysis in sickle cell disease, and investment in SENTRY clinical program

New data from a post hoc analysis of the Phase II SUSTAIN study of crizanlizumab -- a once-a-month, humanized anti-P-selectin monoclonal antibody...


Nov 02, 2018, 17:27 ET Novartis data at ASH and SABCS show strength of pipeline and portfolio in hematology and oncology

Novartis will present new research that may transform the way serious blood diseases and a certain type of breast cancer are treated at the upcoming...


Sep 20, 2018, 09:17 ET Novartis teams up with recording artist and actress Jordin Sparks and SCDAA to launch Generation S, an inspiring new sickle cell storytelling project

Novartis is teaming up with Grammy®-nominated singer, film and Broadway star Jordin Sparks and the Sickle Cell Disease Association of America, Inc....


Sep 12, 2018, 17:02 ET Novartis announces NEJM publication of landmark PARADIGMS study demonstrating significant benefit of Gilenya® in children and adolescents with relapsing multiple sclerosis

Novartis today announced that The New England Journal of Medicine (NEJM) has published full results from the landmark Phase III Gilenya® (fingolimod) ...


Jul 18, 2018, 12:59 ET Novartis Kisqali® now first and only CDK4/6 inhibitor indicated in US as first-line therapy specifically for premenopausal women; and as initial therapy with fulvestrant in postmenopausal women

Novartis today announced a new approval for Kisqali® (ribociclib) from the US Food and Drug Administration (FDA) for women with hormone-receptor...


Jul 12, 2018, 07:15 ET Novartis launches the Galaxies of Hope app, a digital experience for the Neuroendocrine Tumor (NET) cancer community

Novartis today launched its Galaxies of Hope app, a unique digital experience created to support the neuroendocrine tumor (NET) community. Galaxies...


Jul 06, 2018, 16:15 ET Sandoz Inc. and its affiliate, Novartis Pharmaceuticals Corporation, voluntarily recall select blister packages of products in the U.S. due to packaging requirements for child resistance

Sandoz Inc. (Sandoz) and its affiliate, Novartis Pharmaceuticals Corporation (Novartis), today announced a voluntary recall and corrective action...


Jun 19, 2018, 04:02 ET Novartis receives FDA approval for inclusion of new evidence that Cosentyx® inhibits progression of joint structural damage in psoriatic arthritis

Novartis announced today that the US Food and Drug Administration (FDA) approved the inclusion of new evidence that Cosentyx® (secukinumab)...


Jun 15, 2018, 07:00 ET Novartis survey uncovers real-world impact of immune thrombocytopenia or ITP, a rare blood disease, on patients' quality of life

Many patients with the rare blood disorder immune thrombocytopenia (ITP) find the disease has a negative impact on their everyday quality of life,...


May 30, 2018, 07:00 ET FDA expedites review of Novartis drug Promacta® for first-line severe aplastic anemia (SAA)

Novartis announced today that the US Food and Drug Administration (FDA) has accepted the company's supplemental New Drug Application (sNDA) and...


May 17, 2018, 09:35 ET Novartis data at ASCO and EHA reinforce company's commitment to reimagining cancer

Novartis will present data from across its oncology portfolio at the upcoming 54th Annual Meeting of the American Society of Clinical Oncology (ASCO) ...


May 11, 2018, 06:35 ET Novartis announces FDA approval of Gilenya® as the first disease-modifying therapy for pediatric relapsing multiple sclerosis

Novartis today announced that the US Food and Drug Administration (FDA) has approved Gilenya® (fingolimod) for the treatment of children and...


Jan 16, 2018, 01:21 ET Novartis new data reinforces superiority of Cosentyx® versus Stelara® in achieving skin clearance for psoriasis patients

Novartis announced today results from the head-to-head CLARITY study demonstrating the superiority of Cosentyx® (secukinumab) compared to Stelara®...


Jan 04, 2018, 07:15 ET Novartis drug Promacta® receives FDA Breakthrough Therapy designation for first-line use in severe aplastic anemia (SAA)

Novartis today announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to Promacta® (eltrombopag) for...


Jan 03, 2018, 07:15 ET Novartis Kisqali® received FDA Breakthrough Therapy designation for initial endocrine-based treatment in premenopausal women with HR+/HER2- advanced breast cancer

Novartis today announced Kisqali® (ribociclib) received US Food and Drug Administration (FDA) Breakthrough Therapy designation for initial...


Dec 11, 2017, 10:03 ET Novartis drug crizanlizumab shown to prolong time to patients' first sickle cell pain crisis in subgroup analysis of SUSTAIN study

Results from a post hoc subgroup analysis of the Phase II SUSTAIN study show that crizanlizumab, an investigational humanized anti-P-selectin...


Dec 07, 2017, 15:02 ET Novartis initiates study evaluating impact of higher dosing of Cosentyx® in patients with ankylosing spondylitis

Novartis announced today the initiation of the ASLeap trial in patients with ankylosing spondylitis (AS), evaluating the effect of changing to a...


Dec 06, 2017, 12:15 ET Novartis Kisqali® is first and only CDK4/6 inhibitor to show superior median PFS compared to oral endocrine therapy as first-line treatment in a prospective, randomized Phase III trial dedicated to premenopausal women with HR+/HER2- advanced breast cancer

Novartis today announced results from the Phase III MONALEESA-7 trial in premenopausal or perimenopausal women with hormone-receptor positive, human...


Nov 14, 2017, 06:15 ET Novartis presents new data at SABCS across broad range of breast cancer patient populations, combination treatments and lines of therapy

Novartis will present data across its breast cancer portfolio and pipeline in a broad range of patient populations, treatment combinations and...


Nov 01, 2017, 09:14 ET Novartis presents data at ASH for patients with serious blood disorders like lymphoma, leukemia and sickle cell disease

Novartis will present new data from across its hematology portfolio at the upcoming 59th American Society of Hematology (ASH) Annual Meeting &...


Oct 24, 2017, 08:00 ET Novartis collaborates with pop icon Cyndi Lauper to release new song in honor of World Psoriasis Day

Novartis announced today that Grammy, Tony and Emmy award-winning singer, songwriter, actress and activist Cyndi Lauper has released a new song,...


Sep 14, 2017, 07:30 ET Novartis teams up with actress, producer and activist Eva Longoria to launch Kiss This 4 MBC™ to generate research funding and support for the metastatic breast cancer community

Novartis is teaming up with actress, producer and activist Eva Longoria to launch Kiss This 4 MBC™, a new initiative to increase much-needed research ...


Jul 14, 2017, 15:51 ET Novartis confirms 5 year data for first and only fully-human IL-17A inhibitor Cosentyx® reinforcing sustained efficacy and safety profile in psoriasis

Novartis, a global leader in Immunology & Dermatology, confirmed today positive 5 year efficacy and safety results for Cosentyx® from a Phase III...


May 26, 2017, 16:02 ET Novartis receives FDA approval for expanded use of Zykadia® in first-line ALK-positive metastatic non-small cell lung cancer (NSCLC)

Novartis today announced the US Food and Drug Administration (FDA) approved the expanded use of Zykadia® (ceritinib) to include the first-line...